Current Competition in the Nonalcoholic Steatohepatitis Market

Monday, April 26, 2010 Research News
Email Print This Page Comment bookmark
Font : A-A+

Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016 This is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the
global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly
the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector.( ) The Nonalcoholic Steatohepatitis Market is Forecast to Show Marginal Growth between 2009 and 2016 It estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1.8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease) which often progresses to liver cirrhosis. The increased prevalence of diabetes obesity and hyperlipidemia are considered to be important causes of NASH. Antioxidants anti-diabetic medications anti-obesity medications and antihyperlipidemics are some of the off-label products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants the market landscape in future is expected to remain static without any significant dynamism. Overall between 2009 and 2016 the NASH market is expected to grow at a Compound Annual Growth Rate (CAGR) of only 8.4% to reach $3.1bn by 2016. The Current Competition in the Nonalcoholic Steatohepatitis Market is Weak It found that the current competition in the NASH market is weak. The market is devoid of any treatments being approved by the FDA (Food & Drug Administration) or the EMEA (European Medicines Agency) for the treatment of NASH. This is due to the poor understanding of the pathophysiology of the disease and also the niche symptoms the disease which often means it goes unnoticed. The off-label usage of drugs like anti-diabetics anti-hyperlipidemics antioxidants anti-obesity drugs in general is aimed at managing the conditions that contribute to NASH or make it worse. These include obesity high cholesterol and diabetes. However the most effective mode of treatment remains making life style changes and maintaining a modified diet with regular exercise. Weak Pipeline Hindering the Future Growth of the Nonalcoholic Steatohepatitis Market It identified that the pipeline in the NASH market is weak. Though research into the disease market is at a prominent level there is a significant level of activity in Phase II. The late stage pipeline of NASH is very weak. Phase II has molecules like Raptor’s DR cysteamine (Delayed Release Cysteamine) Gilead Science’s GS-9450 Axcan Pharma’s HD-UDCA (High Dose Ursodesoxycholic Acid) Eli Lilly’s Byetta and Enzo Biochem’s EGS21 which have shown promising results. There seems to be little possibility that these molecules will be approved for the treatment of NASH by 2016. Huge Unmet Needs Exist in the Nonalcoholic Steatohepatitis Market The NASH market poses huge unmet needs. This is due to lack of disease understanding low diagnosis rates low prescription rates and low treatment seeking rates. Thus NASH continues to present opportunities for stronger pipeline candidates. However if any company wants to capture the high unmet need posed by the existing market it will need to overcome the prevailing product weaknesses and the adverse effects of the off-label products used in the treatment of NASH. To know more and to buy a copy of your report feel free to visit : Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: Website: Blog: Follow us on twitter:

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store